UNSPSC 51332879: Trifluoperazine dimaleate

This classification denotes a phenothiazine and antipsychotic agent with the molecular formula C21H24F3N3S.2C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AN9ZJ2YUI0, chemically known as phenothiazine, 10-(3-(4-methyl-1-piperazinyl)propyl)-2-(trifluoromethyl)-, maleate (1:2), but more generally known as trifluoperazine dimaleate, which bears US NIH Compound Identifier 6438223.

European Medicines Agency schedules trifluoperazine dimaleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11288MIG. Most nations, for tariff purposes, schedule trifluoperazine dimaleate under HS 29343090. SMILES: CN1CCN(CC1)CCCN2C3C(CCC(C3)C(F)(F)F)SC4C2CCCC4.C(=C\C(=O)O)\C(=O)O.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51332879 Trifluoperazine dimaleate is a Commodity code that in practice captures state and local procurement of pharmaceutical products, though recent solicitations under this code span a wider range of products than the specific drug name suggests—including naloxone, generic multi-source pharmaceuticals, over-the-counter items, and direct-to-manufacturer prescription programs. State and local buyers soliciting under this code include county health departments (Seminole County, Florida), state health and human services agencies (Texas HHS Commission), and cooperative purchasing alliances serving multiple state and local jurisdictions (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP). The work involves competitive bidding for pharmaceutical supply contracts with requirements for FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act adherence, insurance coverage ranging from $2 million to $5 million per occurrence depending on coverage type, and quarterly or ongoing deliveries to government health facilities.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County issued IFB 60459723LAS (closed July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to its Community Health Building in Sanford; the Texas HHS Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer prescription programs before a formal RFP; and MMCAP issued RFP S1070000015802 in January 2026 (proposals due March 26, 2026) for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen, Cardinal Health, and Morris & Dickson) with awards effective July 1, 2026. The MMCAP procurement evaluated proposals on fixed pricing (10 percent), administrative compliance (5 percent), EDI capability (5 percent), 3 percent administrative fee agreement (5 percent), and price competitiveness (75 percent), with a two-year initial contract term and optional extensions.